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Introduction: Pulmonary Langerhans cell histiocytosis (PLCH) is a rare cause of interstitial lung disease characterized by formation of
nodules in the active phase of the disease that evolve into nonactive cystic lesions later on. To evaluate PLCH activity in patients, we
developed a new method for measuring diffuse metabolic activity on fluorine-18-fluorodeoxyglucose positron emission tomography/
computed tomography (FDG-PET/CT) using a lung-to-liver activity ratio.
Material and Methods: We retrospectively studied a series of 4 FDG-PET and 23 FDG-PET/CT scans from 7 patients with PLCH and
analyzed a sample of 100 randomly chosen FDG-PET/CT studies free from any known lung or hepatic diseases. Maximum standardized
uptake value (SUVmax) in a spherical volume (6–8 cm in diameter) in the right lung was put into relation with SUVmax in a spherical
volume (9–10 cm in diameter) in the reference liver parenchyma to set up the SUVmaxPULMO/SUVmaxHEPAR index. The index values
were compared to the disease course in each patient.
Results: In patients with PLCH, a close correlation between the index value and the disease course was found in all seven subjects, where the
increasing index values indicated disease activity, while decreasing index values were observed after therapy administration. In the group of
100 healthy control subjects, we found index values lower than 0.3 in 80% and lower than 0.4 in 96% [range: 0.14–0.43; 0.24±0.07 (100)].
Conclusion: Measuring SUVmaxPULMO/SUVmaxHEPAR values and their time-trend monitoring represent simple, noninvasive screening
tools allowing an early diagnosis and treatment response follow-up assessment in patients with PLCH.
© 2011 Published by Elsevier Inc.Keywords: Langerhans cell histiocytosis; Interstitial lung disease; Positron emission tomography; Pulmonary function tests; High-resolution computed
tomography (HRCT)34
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371. Introduction
Pulmonary Langerhans cell histiocytosis (PLCH) is a rare
condition, the symptoms of which are nonspecific and38
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doi:10.1016/j.nucmedbio.2011.10.002include cough, chest pains and dyspnea, and sometimes,
even pneumothorax may be its first manifestation. In the
early stages of the disease, small nodules evolving through
cavitated forms into thick-walled, later thin-walled and
eventually confluent cysts, and start to build up in pulmonary
parenchyma. These changes predominantly affect upper lung
zones with relative sparing of the lung bases [1]. Radiolog-
ical appearance of advanced PLCH on conventional
radiographs or even high-resolution computed tomography
(HRCT) scans may be difficult to distinguish from
emphysema, which often leads to delays in getting the
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2 P. Szturz et al. / Nuclear Medicine and Biology xx (2011) xxx–xxxright diagnosis and initiating proper treatment. In addition,
X-ray findings are sometimes inconclusive without any
correlation to serious clinical symptoms (Fig. 1).
Langerhans cell histiocytosis limited only to pulmonary
parenchyma is a smoke-related interstitial lung disease
referred to as isolated PLCH, and it has a better prognosis
than Langerhans cell histiocytosis with multisystemic
involvement including lungs. Although having different
prognoses and therapeutic approaches, these two entities
present the same clinical, radiological and histopathological
manifestations [2,3]. PLCH is responsible for 3%–5.5% of
interstitial lung diseases [4–6]. Larger epidemiologic data
are available from Japan [7], where the estimated crude
prevalences in males and females are 0.27 and 0.07 per
100,000 population, respectively. Most patients with PLCH
are young cigarette smokers between 20 and 40 years of
age [1].
Diagnostics include surgical lung biopsy and bronchoal-
veolar lavage with CD1a+ elements (Langerhans cells)
analysis [8]. Additionally, in the setting of multisystemic
Langerhans cell histiocytosis, characteristic HRCT scan
findings in the lungs may be sufficient for the diagnosis.
Treatment is indicated in patients with multisystem involve-
ment or when a progression of pulmonary lesions has beenFig. 1. Different radiological imaging modalities of the chest in a patient with multi
born 1955). The patient presenting with fevers and dyspnea was admitted to hospit
on conventional radiography (1), in contrast to HRCT imaging (3 and 4) showing a
both lung fields resembling emphysema, which was visualized using 3D reconst
accidental finding in this patient. However, retrospective analysis of the SUVmaxP
2010) shows a high probability of a previous history of PLCH (Table 2).confirmed. The progression is characterized by increasing
numbers of nodules, whereas formation and enlargement of
cysts are only a natural disease development into its terminal,
end-stage phase. HRCT scans and pulmonary function tests
are routinely applied in the follow-up; however, determining
the number of nodules on HRCT scans is extremely difficult
and time consuming, and pulmonary function tests cannot
always distinguish between end-stage cystic disease and
active PLCH [6,9].
To facilitate the PLCH activity assessment, we developed
and verified a new method for measuring diffuse metabolic
activity on fluorine-18-fluorodeoxyglucose (FDG) positron
emission tomography/computed tomography (PET/CT) scan
imaging using the SUVmaxPULMO/SUVmaxHEPAR
index. In this paper, we describe this methodology and
verify its validity on a retrospective study of a PLCH
patient cohort.2. Materials and methods
2.1. Patients
During a 21-year period from November 1, 1989, to
January 1, 2011, 23 patients were diagnosed with Langerhanssystemic Langerhans cell histiocytosis with pulmonary involvement (female,
al with suspected pneumonia in July 2010. There were no abnormalities seen
part from hypostatic pneumonia also diffuse small cysts (4–15 mm in size) in
ruction (2). Cystic lung disease, complicated by bacterial infection, was an
ULMO/SUVmaxHEPAR index in preceding four PET examinations (2004–
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3P. Szturz et al. / Nuclear Medicine and Biology xx (2011) xxx–xxxcell histiocytosis and followed up at our department. Out of
them, 15 patients had either single-systemic (nine patients)
or multisystemic (six patients) disease without pulmonary
involvement. The remaining eight patients were diagnosed
with PLCH, of whom seven underwent FDG-PET scan
imaging. In total, 4 FDG-PET and 23 FDG-PET/CT studies
were performed between the years 2004 and 2010. The study
follow-up period started with the first FDG-PET examination
in March 2004.
The indications for FDG-PET or FDG-PET/CT scanning
included: (a) searching for multiorgan involvement of an
extrapulmonary (verified by bone, lymph node or skin
biopsies) Langerhans cell histiocytosis (four scans) as well as
(b) of known PLCH (two scans), (c) differential diagnosis of
pituitary stalk infiltration (one scan) and (d) follow-up of
patients (20 scans). The patients were free from any other
active lung or liver disease at the time of PET scanning. The
diagnosis of PLCH was based on pathological examinations
(three patients) or pathognomonic HRCT scan findings (four
patients). Patients who did not agree to the use of their
medical records for research were not included in this study.
2.2. FDG-PET/CT scan imaging
In the PLCH patient cohort, we performed FDG-PET and
FDG-PET/CT scanning in euglycemia after fasting for 6 h.
FDG-PET scan images of the body, at the extent from the
proximal thirds of femurs to the cranial base (with includedFig. 2. SUVmax in a spherical volume (6–8 cm in diameter) in the right lung was p
the reference liver parenchyma to set up the SUVmaxPULMO/SUVmaxHEPAR
liver, we were more limited in demarcating the volume of interest in the lung parethe head in four scans), were obtained 60 min after
intravenous injection of fluorodeoxyglucose (range of
applied activity: 312–409 MBq). Until 2008, data acquisi-
tion was performed on a PET scanner (ECAT ACCEL
SIEMENS) in a three-dimensional (3D) mode and, later,
from 2008, on a hybrid PET/CT scanner (True Point PET-CT
Biograph 64 SIEMENS). Emission and transmission scans
were reconstructed by using an iterative reconstruction
algorithm. On acquired data, attenuation correction was
applied. Due to repeated follow-up FDG-PET/CT scanning,
in most studies, low-dose CT protocol reducing radiation
load significantly was used. With the remaining studies,
high-dose CT mode was applied. The scan field of view was
50 or 70 cm according to a patient's body habitus. The
acquisition parameters for CT were as follows: slice 5 mm,
collimation 24×1.2 mm, pitch 0.8 mm. To optimize lung
parenchyma imaging, the following reconstruction algorithm
was used: slice 1.5–2.0 mm, kernel B 80 f (ultra sharp),
reconstruction increment 0.4 mm, window–lung. Maximum
standardized uptake values (SUVmax) were measured for
semiquantitative analysis.
2.3. SUVmaxPULMO/SUVmaxHEPAR index
Nodules in PLCH often measure several millimeters (4–6
mm) and are below detectable levels of used PET scanners
(about 7 mm), which precludes direct measurement of their
activity. Therefore, we tried to find these active lesions in aut into relation with SUVmax in a spherical volume (9–10 cm in diameter) in
index. Considering the topographical differences between the lungs and the
nchyma, which therefore has smaller diameter.
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Fig. 3. Box plot of SUV data of control group: median SUVmaxPULMO=
0.70 [range: 0.380–1.600; 0.74±0.26 (100)], median SUVmaxHEPAR=
3.00 [range: 2.40–4.00; 3.11±0.35 (100)], median SUVmaxPULMO/
SUVmaxHEPAR=0.22 [range: 0.14–0.43; 0.24±0.07 (100)].
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4 P. Szturz et al. / Nuclear Medicine and Biology xx (2011) xxx–xxxlarger area. Considering the anatomical conditions, we chose
the volume of interest shaped into spheres of 6–8 cm in
diameter in the right lung. The metabolic activity was
measured in the right upper and middle lung fields. These are
the regions of predominant PLCH involvement. The right
side without heart and pericardium is more suitable for
demarcating the volume of interest and requires only the
exclusion of the hilar structures and pleura, where the
activity can be increased physiologically. Moreover, in the
lower lung fields, numerous motion artifacts are common.
This selection of size and location of the volume of interest
strives to maximize the probability of occurrence of the
majority of active lesions in the most anatomically suitable
region while preserving an easy way of determination in a
daily routine.
To decrease the variability between single examinations
as well as to compare examinations from different scanners,
lung-to-liver activity ratio was assessed. In the liver
parenchyma, we chose volume of interest shaped into
spheres of 9–10 cm in diameter following analogous
principles as in the lungs (Fig. 2). Consequently, SUVmax
in the right lung and SUVmax in the reference hepaticTable 1
Main demographic and clinical characteristics of seven patients with PLCH
Date of birth, sex Smoking habitus Disease
onset (years)
1972, M Smoker 21
1974, M Smoker 33
1969, M Ex-smoker 39
1963, M Active and passive smoker 43
1973, M Smoker 34
1963, M Smoker 45
1955, F Nonsmoker 22parenchyma were measured, and their relationship expressed
as the SUVmaxPULMO/SUVmaxHEPAR index was deter-
mined and used for PLCH activity evaluation.
In our analysis of a sample of 100 randomly chosen
FDG-PET/CT studies free from any known lung or
hepatic diseases, either oncological or nononcological, we
found index values lower than 0.3 in 80% and lower than
0.4 in 96% [range: 0.14–0.43; 0.24±0.07 (100)]. No index
values higher than 0.5 were identified in the healthy
population. The range of applied activity was 302–425
MBq [354.51±32.12 (100)], and that of blood glucose levels
was 3.1–8.1 mmol/L [5.00±1.09 (100)]. Further SUV data
are summarized in Fig. 3.3. Results
Six males, all with a history of smoking, and one female,
31 to 48 years of age at the time of first FDG-PET scanning
[39.7±6.5 (7)], were included in this study. The mean follow-
up period was 17 months [range: 9–79 months; 30.4±29.0
(7)]. Six patients had a multisystemic Langerhans cell
histiocytosis with pulmonary involvement and received at
least one line of therapy. One patient had isolated PLCH, and
this patient has not been treated yet. In patients with
multisystemic disease, the following organs were affected:
lungs (100%), skin (65%), bones (50%), brain (30%), ear
(30%) and lymph nodes (15%). Respiratory symptoms
(dyspnea, cough) were present in five patients (71%), of
whom one patient suffered from recurrent pneumothorax.
Demographic and clinical data are shown in Tables 1 and 2.
All patients underwent FDG-PET scan imaging (4 PET
scans and 23 PET/CT scans). The acquired data, summarized
in Table 3, were correlated to the clinical course of the
disease, HRCT findings, pulmonary function tests and
pathological examinations. In total, 18 HRCT studies
[2.6±1.3 (7)] and 13 pulmonary function tests [1.9±1.5 (7)]
were performed in seven patients. We have found a close
correlation between the SUVmaxPULMO/SUVmaxHEPAR
index values and the above-mentioned disease activity
parameters (Table 2). Consequently, we worked with two
variables, the index value and the metabolic tumor activity,
and found a relationship with positive slope, i.e., increasing
index value corresponds with increasing metabolic tumorExtrapulmonary involvement Diagnosis of pulmonary
involvement (years)
Bones 34
Skin, brain (pituitary stalk), ear 34
Skin 40
Ear 45
Skin, bones, lymph nodes 35
Isolated PLCH 45
Skin, bones, brain, ear 54
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Table 2t2:1
Correlation between the SUVmaxPULMO/SUVmaxHEPAR index and disease course in seven patients with PLCHt2:2
t2:3 Date of
birth, sex
Date of
PET-CTa
SUVmax
PULMO/SUVmax
HEPAR
Disease course and symptoms of
pulmonary involvement
Interpretation of SUVmaxPULMO/SUVmaxHEPAR
index in relation to disease course
t2:4 1972, M Mar 04 0.44 After 5 cycles of cladribine therapy, remission
of bone lesions
High index value due to active smoking
t2:5 Jan 05 0.45 Lasting remission of bone lesions
t2:6 Feb 07 0.51 Dyspnea, cough Progression of PLCH
t2:7 Jun 08 0.47 Smoking cessation leading to relief of symptoms Gradual remission of PLCH in accordance with
relief of symptoms after cessation of smoking
t2:8 Jan 09 0.29
t2:9 Feb 10 0.27
t2:10 1974, M Mar 09 0.21 Screening admission PET/CT
t2:11 Feb 10 0.27 Progression of pituitary stalk infiltration on
brain MRI; therapy initiation
Increased index value suggests progression in lungs
t2:12 Jun 10 0.22 Regression of pituitary stalk infiltration
after 3 cycles with cladribine
Therapy effective also in PLCH as suggested by
decreasing index value
t2:13 1969, M May 09 0.57 Disease activity (recurrent pneumothorax, 3 times);
therapy initiation
High index value confirms PLCH
t2:14 Mar 10 0.22 After 6 cycles of cladribine therapy, partial
remission of skin lesions
Therapy effective in PLCH as suggested by
decreasing index value
t2:15 1963, M Mar 09 0.57 Screening admission PET/CT High index value confirms PLCH
t2:16 Aug 09 0.53 After 4 cycles of cladribine therapy Gradual remission of PLCH after successful
cladribine therapy
t2:17 Mar 10 0.38 Follow-up PET/CT
t2:18 1973, M Jan 09 0.54 Screening admission PET/CT; dyspnea, cough High index value confirms PLCH
t2:19 Jun 09 0.31 After 4 cycles with cladribine therapy Therapy effective also in PLCH
t2:20 Nov 09 0.36 1st relapse (confirmed by lymph node and
skin biopsies); cough
Increased index value suggests relapse in lungs
t2:21 Jan 10 0.27 After 2 cycles of salvage chemotherapy CHOEP;
relief of symptoms
Remission of PLCH after chemotherapy
t2:22 Jul 10 0.28 4 months after autologous transplantation Lasting remission of PLCH after
autologous transplantation
t2:23 Oct 10 0.48 2nd relapse (confirmed by lymph node biopsy) Increased index value suggests 2nd relapse in lungs
t2:24 1963, M Jul 08 0.21 Screening admission PET/CT; intermittent cough
t2:25 Feb 10 0.24 Stable disease not requiring therapy;
lasting intermittent cough
Slightly increased index value in patient with stable
clinical manifestation, but still continuing his
smoking habitus
t2:26 1955, F Mar 04 0.42 Screening admission PET/CT; slight effort dyspnea High index value suggests pulmonary involvement
t2:27 Jan 09 0.31 After several cycles with vinblastine,
prednisone and etoposide
Therapy effective also in PLCH
t2:28 Mar 10 0.14 Progression in brain; therapy initiation Further remission of PLCH
t2:29 May 10 0.17 After 2 cycles with cladribine Lasting remission of PLCH
t2:30 Oct 10 0.38 Further progression in brain, chemoresistant disease Increased index suggests progression of PLCH
CHOEP, cyclophosphamide+doxorubicin+vincristine+etoposide+prednisone.t2:31
a Between 2004 and 2007, only PET scans were made.t2:32
5P. Szturz et al. / Nuclear Medicine and Biology xx (2011) xxx–xxxactivity and vice versa. The increasing trends of index
values were seen in five patients, where they indicated
PLCH activity (i.e., pulmonary symptoms, formation of
nodules on HRCT or abnormal pulmonary function tests),
whereas decreasing trends of index values were observed in
six patients after therapy administration, signaling reduced
metabolic tumor activity. Furthermore, in four patients,
SUVmaxPULMO/SUVmaxHEPAR index values higher
than 0.5 proved to be diagnostic for pulmonary involve-
ment, demonstrating its role as a strong positive predictive
marker. Fig. 4 shows the disease course with corresponding
index values in one patient (male, born 1973).
Quantitative analysis of HRCT findings in patients with
PLCH, consisting of assessment of the exact count ofnodules and cystic formations, is almost impossible to be
obtained. Therefore, the PET-CT findings were correlated to
a semiquantitative radiological evaluation of HRCT scans,
and neither sensitivity, specificity, accuracy nor predictive
values can be exactly calculated in our study.4. Discussion
The clinical course of PLCH is very divergent and
impossible to be predicted for an individual patient [2,3].
About 50% of patients with isolated PLCH have a favorable
prognosis with total disease remission, i.e., reduction of
pulmonary nodules either spontaneously or after corticoid
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Table 3t3:1
An overview of PET-CT data in 7 patients with PLCHt3:2
t3:3 Date of
birth, Sex
Date of
PET-CTa
Applied
activity (MBq)
Blood glucose
levels (mmol/L)
SUVmax
PULMO
SUVmax
HEPAR
SUVmax
PULMO / SUVmax
HEPAR
t3:4 1972, M Mar-04 327 4.4 0.80 1.83 0.44
t3:5 Jan-05 321 5.8 0.81 1.79 0.45
t3:6 Feb-07 335 4.1 1.02 2.01 0.51
t3:7 Jun-08 337 4.8 1.06 2.24 0.47
t3:8 Jan-09 315 5.2 0.92 3.22 0.29
t3:9 Feb-10 352 4.7 0.89 3.25 0.27
t3:10 1974, M Mar-09 414 4.6 0.93 4.39 0.21
t3:11 Feb-10 431 4.8 0.89 3.25 0.27
t3:12 Jun-10 466 5.4 0.78 3.53 0.22
t3:13 1969, M May-09 377 4.7 1.88 3.30 0.57
t3:14 Mar-10 393 5.2 0.78 3.53 0.22
t3:15 1963, M Mar-09 372 4.7 1.78 3.11 0.57
t3:16 Aug-09 421 4.9 1.79 3.36 0.53
t3:17 Mar-10 401 4.7 1.03 2.71 0.38
t3:18 1973, M Jan-09 330 6.3 1.34 2.49 0.54
t3:19 Jun-09 336 5.6 0.68 2.23 0.31
t3:20 Nov-09 330 5.3 1.18 3.24 0.36
t3:21 Jan-10 338 5.7 0.88 3,30 0.27
t3:22 Jul-10 317 5.5 0.75 2.72 0.28
t3:23 Oct-10 292 6.4 1.40 2.98 0.48
t3:24 1963, M Jul-08 338 4.7 0.69 3.30 0.21
t3:25 Feb-10 354 5.1 0.95 3.96 0.24
t3:26 1955, F Mar-04 344 4.4 1.02 2.45 0.42
t3:27 Jan-09 337 5.8 1.00 3.19 0.31
t3:28 Mar-10 357 6.7 0.48 3.49 0.14
t3:29 May-10 351 5.4 0.53 3.15 0.17
t3:30 Oct-10 386 7.0 1.45 3.8 0.38
a Between 2004-2007 only PET scans were made.t3:31
6 P. Szturz et al. / Nuclear Medicine and Biology xx (2011) xxx–xxxtherapy. Cessation of smoking proved to be essential in
therapy management, leading to remission in many cases
described [6,10,11]. Nevertheless, cystic lung damage is
irreversible. Moreover, PLCH implies a higher risk of lung
cancer, especially in smokers, and a higher risk of other
malignancies as well [12].
The greatest challenge is the evaluation of PLCH disease
activity and, consequently, therapy effectiveness. In recent
years, based on a contrasting rate of glucose utilization
between rapidly proliferating tumor cells and surrounding
normal tissue, much attention has been devoted to the benefit
of FDG-PET and FDG-PET/CT scan imaging for determin-
ing the extent of Langerhans cell histiocytosis and therapy
response evaluation.
Derenzini et al. [13] used FDG-PET for evaluating the
effectiveness of MACOP-B chemotherapy in four patients.
The FDG-PET scan was able to detect additional lesions
missed by other modalities in two patients. A negative
interim FDG-PET predicted a long-lasting remission in three
of four patients. Phillips et al. [14] published the same
experience as they compared the benefit of FDG-PET/CT to
bone scans, CT, magnetic resonance imaging (MRI) and
conventional radiography for determining the extent of
Langerhans cell histiocytosis and evaluation of therapy
response in 44 patients (41 children and 3 adults). Theyconcluded that whole-body FDG-PET scans can detect
disease activity and early response to therapy with greater
accuracy than other imaging modalities in patients with
Langerhans cell histiocytosis affecting bones and soft
tissues. Furthermore, FDG-PET is also beneficial for an
early diagnosis of neurodegenerative Langerhans cell
histiocytosis [15].
However, a MEDLINE literature search revealed only
one paper evaluating FDG-PET scan imaging in PLCH, the
work from authors Krajicek et al. [16], who described their
cohort study with 11 patients. PET-scan-positive patients
had predominantly nodular lung disease with more than 100
nodules usually under 8 mm in size, whereas PET-scan-
negative patients had predominantly cystic lung disease with
nodules numbering less than 25 in a field of examination.
In our study, all pathology in the lung parenchyma was
below detectable levels of the PET scanner (less than 7 mm),
and we did not find large active lesions. Notwithstanding the
observations of Krajicek et al., we describe a new
methodology for diffuse metabolic activity evaluation of
the lung parenchyma and present the possibility to objectify
the results by comparing them with the simultaneously
measured activity of the reference liver parenchyma. The
evaluation of pulmonary activity based on the index, the ratio
of the measured SUVmax value in a spherical volume of the
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Fig. 4. Series of FDG-PET/CT images of a patient with multisystemic Langerhans cell histiocytosis with pulmonary involvement (male, born 1973). High index
value on admission PET/CT together with pathognomonic HRCT finding (multiple small nodules with sporadic cysts) and clinical symptoms (dyspnea, cough)
was diagnostic for PLCH. Interim PET/CT after two cycles with cladribine shows a therapy response which correlated with regression of lymphadenopathy
and relief of the symptoms, including perianal pruritus and B-symptoms (night sweats, fever and weight loss). However, an aggressive form of Langerhans
cell histiocytosis with recurrent relapses was the case. The index value corresponded closely with the disease course. We consider myocardial FDG uptake to
be physiological.
7P. Szturz et al. / Nuclear Medicine and Biology xx (2011) xxx–xxxright lung to the measured SUVmax value in a spherical
volume of the liver — the SUVmaxPULMO/SUVmaxHE-
PAR index — which we propose and which we have
verified, has not been published so far. We are aware of the
fact that the method we used is not common and, with such
small lesions, it is negatively biased by the partial-volume
effect characterized by increasing underestimation of SUV
with decreasing lesion sizes [17]. The index may be
influenced by concomitant factors affecting either lungs or
liver (e.g., other interstitial lung diseases, benign tumors,
active infections or noninfectious inflammations, cholesta-
sis, cirrhosis). Moreover, hyperinsulinemia [18], higherglucose level [19] and advanced age [20] were found to be
related to increased FDG uptake by liver.
Currently, except for HRCT of the lungs and pulmonary
function tests, there is no other modality that informs more
accurately on PLCH activity. Traditional FDG-PET scan
imaging is not possible due to the small size of nodules
which cannot be reliably resolved by the PET scanner.
Therefore, we consider the measuring and long-term
monitoring of the index SUVmaxPULMO/SUVmaxHEPAR
to be very useful additional tools for PLCH activity
evaluation. Based on our analysis of a sample of 100
randomly chosen PET/CT scans, as mentioned above, and on
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8 P. Szturz et al. / Nuclear Medicine and Biology xx (2011) xxx–xxxthis retrospective study, we found that SUVmaxPULMO/
SUVmaxHEPAR index values higher than 0.5 bear high
probability of pulmonary involvement in patients with
Langerhans cell histiocytosis.
In conclusion, measuring the SUVmaxPULMO/SUV-
maxHEPAR index and its time-trend monitoring represent
simple noninvasive screening tools for PLCH, allowing us to
optimize the therapeutic management in the patients. An
early diagnosis of pulmonary involvement with a prompt
initiation of therapy may prevent progressive cystic damage
to the lungs. The index measurement also enables an
effective monitoring of therapy response and follow-up of
patients with PLCH.357
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